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Abstract
The dismal lethality of lung cancer is due to late stage at diagnosis and inherent therapeutic resistance. The incorporation of
targeted therapies has modestly improved clinical outcomes, but the identification of new targets could further improve
clinical outcomes by guiding stratification of poor-risk early stage patients and individualizing therapeutic choices. We
hypothesized that a sequential, combined microarray approach would be valuable to identify and validate new targets in
lung cancer. We profiled gene expression signatures during lung epithelial cell immortalization and transformation, and
showed that genes involved in mitosis were progressively enhanced in carcinogenesis. 28 genes were validated by
immunoblotting and 4 genes were further evaluated in non-small cell lung cancer tissue microarrays. Although CDK1 was
highly expressed in tumor tissues, its loss from the cytoplasm unexpectedly predicted poor survival and conferred resistance
to chemotherapy in multiple cell lines, especially microtubule-directed agents. An analysis of expression of CDK1 and CDK1-
associated genes in the NCI60 cell line database confirmed the broad association of these genes with chemotherapeutic
responsiveness. These results have implications for personalizing lung cancer therapy and highlight the potential of
combined approaches for biomarker discovery.
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Introduction
Lung cancer is the leading cause of cancer death throughout the
world, causing approximately 1.2 million deaths annually and an
estimated 157,300 deaths in the US in 2010 [1]. NSCLC most
commonly occurs in smokers [2]. In the US, approximately 90%
of deaths from lung cancer in men and 79% in women are
associated with smoking [3]. Most lung cancers are of epithelial
cell origin. Therefore, the development of lung cancer reflects the
cumulative effect of smoking-induced molecular changes in airway
epithelial cells. Because approximately 90,000,000 current or
former smokers in the US have a permanently increased relative
risk for developing lung cancer, the identification of early
molecular events inherent to lung tumorigenesis could provide a
basis for interventions aimed at preventing the phenotypic
progression that underlies carcinogenesis.
Molecular changes in lung cancer are complex and include
genetic, epigenetic, and biochemical alterations. The first
molecular events to be identified were genetic and included
inactivation of tumor suppressor genes such as p53 [4], and
activation of oncogenes such as K-Ras [5]. Epigenetic events
include silencing of the CDK inhibitor, p16, the tumor suppressor
RASSF1, and other genes through methylation [6,7]. Recently,
biochemical events such as constitutive activation of signal
transduction pathways that promote cellular survival and thera-
peutics resistance have also been reported [8,9,10]. Ultimately,
these molecular changes must drive phenotypic progression of the
epithelial cell destined for transformation. The experimental
transformation of normal epithelial cells into tumorigenic cells
requires two distinct steps. The first is cell immortalization, which
is required to make cells susceptible to the second step,
transformation. Human cells must circumvent two barriers to
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These barriers to immortalization are regulated by telomere
shortening and by the retinoblastoma (Rb) and p53 tumor-
suppressor pathways [11]. Additional changes are required for full
transformation. Even though an increasing number of molecular
changes have been identified in the phenotypic progression of
epithelial cell transformation, other events are likely important.
To identify a broad range of molecular changes inherent to the
processes of immortalization and transformation of airway
epithelial cells, we used a model system established by Reddel
et al., who created immortalized, non-tumorigenic bronchial
epithelial cells (BEAS-2B) by infecting normal human bronchial
epithelial cells (NHBE) with adenovirus-12 SV40 hybrid virus
[12]. Disruption of p53 and Rb pathways by SV40 T-antigen,
together with increased telomerase expression, immortalized
BEAS-2B cells. BEAS-2B cells were then made fully tumorigenic
by exposing BEAS-2B cells in vivo to the tobacco specific
carcinogen, nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-bu-
tanone (NNK), for 6 months. NNK exposure induced phenotypic
changes in BEAS-2B cells that were similar to the progressive
changes that occur during human lung carcinogenesis [13].
In these studies, we systematically profiled gene expression in
normal (NHBE), immortalized (BEAS-2B) and fully transformed
(NNK-BEAS-2B) human bronchial epithelial cells, as well as a
non-small cell lung cancer (NSCLC) cell line (H157) from a
smoker (Figure 1A). Expression profiles that accompany the
immortalization and/or transformation of bronchial epithelial cells
were generated, and expression of 28 genes was validated by
immunoblotting. 4 of them were further evaluated in immunohis-
tochemical analyses of tissue microarrays that contain NSCLC
specimens, surrounding non-diseased tissues and non-pulmonary
normal tissues. Although all 4 genes were predominantly expressed
in tumor tissues, loss of expression of cytoplasmic CDK1 was
clinically important because it was associated with a poor
prognosis for NSCLC patients. This poor prognostic value may
be associated with therapeutic resistance, because decreasing levels
of cytoplasmic CDK1 in vitro increased resistance to standard
chemotherapies used in the treatment of NSCLC, especially
microtubule agents where resistance was almost complete. These
studies illustrate how a combined microarray approach can
facilitate the identification of new, relevant targets in cancer.
Results
Classification of differentially expressed genes in BEAS-
2B, NNK-BEAS-2B and H157 cells compared to NHBE cells
With NHBE as the reference, 1,688 genes were differentially
expressed in BEAS-2B, NNK-BEAS-2B and/or H157 cells.
Differentially expressed genes were classified into lettered groups
(A-P) based on the distribution of the expression changes
(Figure 1B). Gene expression profiles were grouped based on
phenotypic characteristics. NHBE, BEAS-2B, NNK-BEAS-2B
cells represented normal, immortalized, and transformed stages of
lung carcinogenesis, respectively, and H157 cells were used as an
unrelated fully transformed cell line derived from a NSCLC
patient. Genes in groups A (65, 3.9%) or J (101, 6%) were
upregulated or downregulated, respectively, in BEAS-2B, NNK-
BEAS-2B and H157 cells, indicating that these genes expression
changes were common to the immortalization and transformation
of NHBE. Expression of genes in groups B (38, 2.3%) or I (31,
1.8%) was increased or decreased, respectively, in BEAS-2B and
NNK-BEAS-2B but not H157 cells, suggesting that these changes
resulted from SV40-mediated immortalization. Genes in groups C
(112, 6.6%) or H (39, 2.3%) were differentially expressed in NNK-
BEAS-2B and H157 cells, implicating that these genes contribute
to full cell transformation. Groups D (407, 24.1%) and G (571,
33.8%) comprised the largest number of genes and were specific
for NNK-BEAS-2B cells. This suggests that NNK-mediated
transformation is a complex event that requires changes in
expression of many genes. Other changes in gene expression were
specific for a given cell type, and were excluded from further
analysis. The complete gene list and related ratio data are
provided in supporting information (Table S1).
Gene expression profile annotation and biological
analysis
Among the classifications, groups A and J include genes that are
crucial throughout tumor evolution, from immortalization to
transformation, and groups C and H include genes that are
associated with full transformation. The quantitative changes in
gene expression are shown (Figure 1C). To analyze gene expression
changes of these groups on a genomic scale and provide linkage to
putative biological processes, we performed High-Throughtput
GoMiner analysis (Table 1, the related genes were listed in Table
S2). In group A, genes involved in mitosis were highly enriched. In
group J, genes involved in ectoderm development were diminished.
No significant gene ontology (GO) categories were noted for groups
B and I. In groups C or H where gene expression changes were
associated with transformation, genes involved in mitosis regulation
were enhanced, while genes that negatively regulate cell prolifer-
ation and biological processes were diminished (Table 1). Several
GO categories were noted for groups D and G that are related to
changes associated with transformation by NNK (Table S3). These
results were extended by performing Gene MicroArray Pathway
Profiler analysis, which showed that the cumulative effect of gene
expression changes in carcinogenesis would be predicted to increase
autonomous progression through the cell cycle (Figure S1) and
evasion of apoptosis (Figure S2).
Validation of expression profiles at protein level by
immunoblotting
To validate our microarray data, we performed immunoblotting
for 28 candidate genes drawn from various groups (Figure 2). The
choice of genes was based on the commercial availability of
antibodies that had been previously used in immunoblotting
experiments. Groups A or J represented genes that were over- or
under-expressed in immortalization and transformation, respec-
tively. Compared to NHBE, BEAS2B, NNK-BEAS-2B and H157
cells had increased expression of CDK1, Cyclin A, STMN1,
PTTG1, and TOP2A (group A), and decreased expression of
KRT14, PERP, S100A8, Maspin, TRAIL, and p63 (group J).
When comparing mRNA expression to protein expression in
groups A and J, only p63 appeared misclassified in that p63 was
categorized into group J based on microarray data, but
immunoblotting revealed that decreased p63 expression was only
observed in H157 cells (group N). This could be related to variable
antibody-specific reactivity against p63 isoforms and splice
variants. The genes in groups C or H were classified as
transformation-specific based on microarray data. Immunoblot-
ting revealed that many genes within this group C were
misclassified. For example, Cyclin B2, Galectin1 and PBK
appeared to be predominantly expressed in NNK-BEAS-2B cells
(group D), while Cyr61 and hnRNPA2/B1 were common to cells
that were immortalized and transformed (group A). p21 and KLF4
from group H were accurately classified, because their mRNA and
protein levels were decreased in NNK-BEAS-2B and H157
transformed cells. Groups D or G represented NNK-specific
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sion of Survivin, DNMT1, HIP1, PLK1, SPARC and ETS1
(group D), and downregulated protein expression of p15, FKHR
and TAO1 (group G). The correlation between mRNA expression
and protein expression was high for these groups. XAGE1,
originally classified as an H157 cell-specific gene (group M),
showed greatest expression in H157 cells. Overall, immunoblot-
ting revealed that 22/28 genes (79%) were correctly classified from
the microarray data, indicating a high correlation between mRNA
and protein expression.
Immunohistochemical staining on lung tissue microarray
To determine whether genes that were identified in the
microarray analysis and further validated using immunoblotting
had clinical significance, we performed immunohistochemistry
(IHC) to assess expression in human NSCLC specimens. Of the 22
correctly classified genes, CDK1, TOP2A, PTTG1 and Survivin
were chosen based on commercial availability of antibodies that
had been validated in IHC. Expression was assessed in tissue
microarrays (TMAs) that contain 300 NSCLC cases (150
adenocarcinomas (AD) and 150 squamous cell carcinomas
(SCC)), 100 adjacent non-diseased lung tissues from AD and
SCC cases, and 50 non-pulmonary normal tissues [14]. Scoring
was based on intensity, distribution, and subcellular localization.
Staining patterns for CDK1, PTTG1 and Survivin were similar in
that staining was either predominantly cytoplasmic or both
nuclear and cytoplasmic. In contrast, staining for TOP2A was
either exclusively nuclear or both cytoplasmic and nuclear
(Figure 3A). Compared to tumor cells, staining of surrounding
stromal tissue was minimal or absent.
All four proteins were predominantly expressed in tumor tissues,
compared to the adjacent non-diseased lung tissues (Figure 3B).
This was especially evident when nuclear staining was considered.
Most NSCLC samples were positive for CDK1 cytoplasmic
staining (86% for AD and SCC), and 40% of AD specimens and
36% of SCC specimens showed nuclear staining. Surrounding
normal lung tissues and other normal tissues expressed cytoplasmic
CDK1, but did not express nuclear CDK1. Staining for TOP2A
was overall less prevalent in NSCLC specimens than for the other
proteins (20–34%), but was more evenly distributed between
Figure 1. Classification and annotation of differentially expressed genes in BEAS-2B, NNK-BEAS-2B and H157 compared to NHBE. A.
The system and strategy to study gene expression profile, its clinical significance and functional role during NSCLC carcinogenesis and
chemotherapeutic resistance. B. Classification of 1,688 regulated genes among BEAS-2B (B), NNK-BEAS-2B (NB) and H157 (H) compared to NHBE (N).
Genes whose expression level did not change between cell lines were excluded. The ratios graphically visualized by Cluster and TreeView programs
(http://rana.lbl.gov/EisenSoftware.htm). Pairs of lanes and reciprocal red and green colors indicate dye swapping. C. Gene expression dynamics during
immortalization and/or transformation. The graphs were generated by Cluster Analysis of Gene Expression Dynamics program (http://www.
genomethods.org/caged). A, C, J and H symbols depict groups of genes identified in Figure 1B.
doi:10.1371/journal.pone.0023849.g001
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exclusive to NSCLC specimens vs. surrounding normal lung
tissues. PTTG1 and Survivin showed a high prevalence of
cytoplasmic staining (PTTG1- 79% in AD and 69% in SCC;
Survivin- 73% in AD and 61% in SCC), as well as nuclear staining
(PTTG1- 35% in AD and 49% in SCC; Survivin- 44% in AD and
33% in SCC). Overall, staining for all four proteins was selective
for NSCLC specimens vs. surrounding normal tissues, regardless
of subcellular localization (Figure 3C).
We used two-way clustering to analyze the staining patterns,
and the x
2 test to examine the agreement between each antibody
and the association of antibody staining with clinical factors.
Tumors that stained for TOP2A were most distinct, compared to
CDK1, PTTG1 and Survivin (Figure 4A). The strongest
association of antibody staining was between TOP2A nuclear
and cytoplasmic staining (Table 2), which is consistent with the
observation that TOP2A is localized to the nucleus and often
accompanied by cytoplasmic staining (Figure 3A). In contrast to
TOP2A, staining for CDK1, PTTG1, and Survivin was
predominantly cytoplasmic. Cytoplasmic or nuclear staining for
PTTG1 and Survivin also clustered very similarly, and this was
consistent with the x
2 tests (Table 2). CDK1 nuclear staining was
strongly associated with either nuclear or cytoplasmic TOP2A
staining. Overall, the agreement between staining with these
antibodies was very strong, except for the association of
cytoplasmic CDK1 staining with nuclear Survivin staining
(Figure 4A and Table 2).
When analyzed by stage, staining for all four proteins was
greater in stage 1–2 disease (Figure 4B). This was especially true
for TOP2A nuclear staining, where 56% of stage 1–2 specimens
were positive whereas only 26% of stage 3–4 specimens were
positive. When staining was associated with clinical variables,
there was no relationship with age, gender or differentiation
(Table 2). Cytoplasmic TOP2A staining was strongly associated
with smaller tumors (,5 cm) (p=0.00745), and cytoplasmic
Survivin staining was associated with stage I disease (stage 1.stage
2-3-4, p=0.0436) (Table 2).
Only cytoplasmic CDK1 staining was associated with survival,
although there was a trend toward worse survival with cytoplasmic
PTTG1 positive patients with tumors ,5c m( p=0.089). Regard-
less of stage, loss of cytoplasmic CDK1 confers a poor prognosis
(p=0.040) (Table 2). Since the number of stage 2 tumors negative
for cytoplasmic CDK1 is too small and prohibited a meaningful
comparison with positive stage 2 tumors, and the overall survival
of patients in this data set with stage 1 and stage 2 patients is
similar, we combined stage 1 and stage 2 tumors as early stage
tumors. When comparing early stage (1 and 2) and advanced stage
tumors (3 and 4), we found that loss of cytoplasmic CDK1 was
borderline significant for early stage tumors (p=0.063) but highly
significant for late stage tumors (p=0.008) (Figure 4C and Table 2).
Table 1. GeneOntology analysis of gene expression signatures during immortalization and/or transformation.
GO category Total Changed Enrichment Log10(p) FDR
A
GO:0007067_mitosis 119 10 14.23 29.00 0.00
GO:0000910_cytokinesis 121 10 14.00 28.93 0.00
GO:0000278_mitotic_cell_cycle 175 11 10.65 28.54 0.00
GO:0007049_cell_cycle 486 15 5.23 27.41 0.00
GO:0000067_DNA_replication_and_chromosome_cycle 9 4 75.25 26.89 0.00
GO:0006259_DNA_metabolism 349 11 5.34 25.47 0.00
GO:0007059_chromosome segregation 40 4 16.94 24.09 0.00
GO:0007088_regulation of mitosis 26 3 19.54 23.35 0.00
GO:0006260_DNA_replication 113 5 7.49 23.30 0.00
GO:0000075_cell_cycle_checkpoint 27 3 18.82 23.30 0.00
GO:0000070_mitotic_sister_chromatid_segregation 31 3 16.39 23.12 0.00
J
GO:0007398_ectoderm_development 50 11 21.06 211.72 0.00
GO:0008544_epidermis_development 42 9 20.52 29.53 0.00
GO:0009888_histogenesis 94 11 11.20 28.61 0.00
GO:0009887_organogenesis 664 20 2.88 25.08 0.00
GO:0009628_response_to_abiotic_stimulus 264 10 3.63 23.43 0.00
C
GO:0007088_regulation_of_mitosis 26 4 14.31 23.81 0.02
GO:0000279_M_phase 148 8 5.03 23.77 0.01
GO:0007067_mitosis 119 7 5.47 23.58 0.01
GO:0000278_mitotic_cell_cycle 175 8 4.25 23.28 0.01
GO:0000398_nuclear_mRNA_splicing_via_spliceosome 70 5 6.65 23.06 0.01
H
GO:0008285_negative_regulation_of_cell_proliferation 108 4 9.06 23.05 0.05
GeneOntology analysis was performed using High-Throughput GoMiner. A, C, J and H symbols depict groups of genes identified in Figure 1B.
doi:10.1371/journal.pone.0023849.t001
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The fact that loss of cytoplasmic CDK1 conferred a poor
prognosis, especially for advanced NSCLC patients who are more
likely to receive chemotherapy or chemoradiotherapy, suggested
it might contribute to chemotherapeutic resistance. To test this
hypothesis, a temperature-sensitive p34CDC2/CDK1 mutant
murine carcinoma FT210 cell line was used. When FT210 cells
are cultured at a non-permissive temperature of 39uCf r o ma
permissive temperature of 32uC, CDK1 becomes preferentially
inactivated and degraded from the cytoplasm [15]. Chemother-
apies typically used to treat NSCLC were tested in these cells at
each temperature. Etoposide, a topoisomerase II inhibitor, or
cisplatin, a DNA damaging agent, significantly increased
apoptosis at the permissive temperature. At the non-permissive
temperature, apoptosis was partially inhibited (Figure 5A).
Similar results were observed at the permissive temperature for
three different microtubule-based therapies, where marked
increases in apoptosis were observed (Figure 5B). In contrast,
under non-permissive conditions, cells were almost completely
resistant to each microtubule-targeted agent. Total levels of
CDK1 protein were decreased at 39uC, as was phosphorylation
of CDK1 at Y15. Phospho-Tyr15 CDK1 is an inactive
cytoplasmic form of CDK1 due to phosphorylation by Myt1.
Cleavage of PARP at each temperature by paclitaxel was
consistent with measurement of apoptosis (Figure 5B). Compared
to its parental cell line FM3A, FT210 cells preferentially lost
cytoplasmic CDK1 protein expression (Figure 5C) and activity
indicated by decreased phosphorylation of survivin at Thr34, a
site for CyclinB-CDK1 kinase [16] (Figure 5D). Paclitaxel caused
significant cytotoxicity in FM3A and FT210 cells at 32uC, but
only FM3A cells at 39uC. Similarly, FM3A cells were killed by
docetaxel and vinorelbine at either 32uCo r3 9 uC (Figure 5E).
Thus, loss of CDK1 in FT210 cells increased relative resistance to
etoposide and cisplatin, but induced marked resistance to
microtubule targeting agents.
We further investigated the role of CDK1 in chemotherapeutic
resistance by modulating levels of CDK1 in human NSCLC cells.
Overexpression of CDK1 in H157 cells slightly elevated basal
levels of apoptosis and potentiated paclitaxel-induced apoptosis
(Figure 6A). In contrast, downregulation of CDK1 in H157 cells
using siRNA conferred resistance to paclitaxel. Similar results were
observed in a separate NSCLC cell line (A549) when CDK1
expression was decreased using siRNA (Figure 6B). Although
knockdown of CDK1 did not affect cell cycle distribution of
untreated A549 cells, it did reduce sub-G1 DNA content and
PARP cleavage when A549 cells were exposed to paclitaxel. The
increase in G2/M fraction with CDK1 knockdown is consistent
with the role of CDK1 at the G2 to M phase transition. To dissect
a role for CDK1 in apoptosis vs. G2/M transition, A549 cells were
transfected with empty vector, wild type CDK1 or dominant
negative CDK1 (CDK1DN) constructs, growth arrested with serum
deprivation and a PI3K inhibitor LY294002, and then treated
with paclitaxel. Diminished cell proliferation was observed
microscopically and confirmed by the lack of G2/M enrichment
with paclitaxel treatment (Figure 6C). Despite cell cycle arrest,
overexpression of CDK1 still increased the sub-G1 fraction that
correlated with loss of the G1 population. These effects were not
seen with overexpression of CDK1DN, which lacks kinase activity
via a dominant point mutation (D146N) [17].
The above experiments demonstrate that CDK1 protein level
and activity is associated with the sensitivity of cancer cells to
chemotherapy. To confirm this observation, we searched the
NCI60 human cancer cell line compound sensitivity and
molecular targets databases and performed COMPARE [18]
analyses. Expression of the CDK1 activator CDC25A, p-Y15/
T14 CDK1, total CDK1, as well as the CDK1 binding partners
cyclin B and cyclin A were positively associated with sensitivity to
paclitaxel, etoposide, and docetaxel. The highest Pearson
Correlation Coefficients (PCC) were observed with docetaxel
and paclitaxel (Table 3). Although CDC25A, p-Y15 CDK1 and
cyclin A were modestly associated with cisplatin, CDK6 and
TYMS were the top correlates. Thus, CDK1 and its activating
machinery components (Figure 7A) were broadly identified as
factors that underlie sensitivity to many agents used to treat human
cancers, especially microtubule-directed agents.
Figure 2. Immunoblotting and comparison of expression
changes between protein and mRNA levels. Immunoblotting
analysis in NHBE (N), BEAS-2B (B), NNK-BEAS-2B (NB) and H157 (H) cells
for 28 Molecules from representative groups, and the comparison of
expression changes with mRNA levels from microarray data.
doi:10.1371/journal.pone.0023849.g002
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The identification of clinically relevant protein targets in cancer
is difficult. We strategically profiled transcriptional alterations in
models of lung carcinogenesis, validated targets at a protein level,
and evaluated expression and subcellular localization of the top
candidates on clinical tissue microarrays. Of the genes identified in
cDNA microarrays and corroborated by immunoblotting, CDK1,
TOP2A, PTTG1 and Survivin were chosen for further evaluation.
CDK1, PTTG1 and Survivin were highly expressed in lung tumor
tissues. Nuclear CDK1 and TOP2A was exclusively expressed in
tumor tissues compared to normal tissues, including non-
pulmonary normal organs. The fact that these genes were
preferentially expressed in tumor tissues, especially in early stage
NSCLC, suggests that they might have utility as biomarkers and
therapeutic targets in early stage NSCLC.
CDK1 is an important, emerging target in cancer. CDK1 is a
catalytic subunit of M-phase promoting factor, which is essential
for G1/S and G2/M phase transitions of the eukaryotic cell cycle.
The highest staining in NSCLC clinical samples and the strongest
expression in tumorigenic NNK-BEAS2B cells suggest that CDK1
plays a pivotal role in tumorigenesis. In fact, overexpression of
CDK1 has been observed in early stage lung adenocarcinomas
[19]. Our data showed that although most NSCLC specimens
expressed cytoplasmic CDK1, its loss conferred a poor prognosis,
especially for advanced NSCLC patients. Loss of cytoplasmic
CDK1 could be explained by loss of total protein expression or
translocation to the nucleus. Very few tumor samples (4 cases)
express nuclear but not cytoplasmic CDK1, suggesting that loss of
proteins such as 14-3-3s that sequester CDK1 in the cytoplasm
might contribute to this finding [20] [21], but loss or reduction of
14-3-3s is very rare in primary NSCLC specimens [4]. Our
chemotherapy experiments demonstrate that lowering total levels
of CDK1 or cytoplasmic levels of CDK1 confers chemotherapeu-
tic resistance to many agents used to treat lung cancer, especially
microtubule-directed agents.
Data derived from the NCI 60 human cancer cell line database
suggests that the status of many components of the CDK1
machinery could potentially play a broad role in sensitivity to
chemotherapy that is not only limited to NSCLC cell lines.
Figure 3. Tissue microarray immunohistochemistry. A. Examples of CDK1, PTTG1, Survivin and TOP2A subcellular staining in clinical tumor
samples (-C: cytoplasmic staining; -N: nuclear staining). Staining is shown at 4006magnification. B. Tissue distribution of positive rates for CDK1,
PTTG1, Survivin and TOP2A. AD: Adenocarcinoma; SCC: Squamous cell carcinoma; N-AD: Adjacent non-diseased lung tissues from Adenocarcinoma;
N-SCC: Adjacent non-diseased lung tissues from squamous cell carcinoma; N-O: Non-pulmonary normal organs. C. Overview of entire tissue
microarray staining for expression of these antigens in the cytoplasm or nucleus.
doi:10.1371/journal.pone.0023849.g003
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cycle progression through activation of CDKs by dephosphory-
lating CDKs at threonine 14 and tyrosine 15, two critical amino
acid residues leading to subsequent association of CDKs with their
associated cyclins. Three homologs exist in mammals: CDC25A,
CDC25B, and CDC25C. CDC25A [22,23,24] and CDC25B
have oncogenic properties and are overexpressed in some types of
tumors [25]. CDC25B and CDC25C are implicated as regulators
of mitosis but loss of these genes in mice or cells does not alter cell
cycle or checkpoint responses, suggesting a possible functional
compensation by CDC25A [26]. The CDC25A protein shuttles
between the nucleus and cytoplasm [27,28] and has a compre-
hensive function in regulating G1/S, S and G2/M transitions
[29]. Thus, CDC25A temporally and spatially has more chances
than CDC25B/C to prematurely activate CDK1. Accompanying
CDK1 dephosphorylation by CDC25A, CDK1 associates with
cyclin A/B and then moves rapidly into the nucleus [30]. The cell
cycle has to be regulated in both time and space [31]. An
unscheduled, premature or sustained CDK1 activation can be lead
to cell death, mitotic catastrophe or apoptosis induction
[32,33,34], especially when CDK1 activating machinery compo-
nents are highly expressed [35]. Phosphorylated CDK1, an
inactive form predominantly in cytoplasm [31], is a substrate for
CDC25A, and its abundance in the cytoplasm enhances the
CDK1 activation potential. This might be the reason why p-Y15/
T14 CDK1 was more positively associated drug sensitivity than
total CDK1 in the COMPARE analysis, and why cytoplasmic
CDK1 loss confers chemotherapeutic resistance and worse
survival in NSCLC patients.
Our High-Throughput GoMiner analysis revealed that mitosis is
the major biological process that is altered during NSCLC
carcinogenesis. Mitotic CDK1 is the only essential cell cycle CDK
to promote unlimited cell division and a key player in oncogenic
growth [36]. However, high level of CDK1 activation might sensitize
tumor cells to stresses either from nutrient depletion or chemotherapy
treatment. Because deficiency in Cdk1 results in no cell division [37],
CDK1 loss from cancer cells is unlikely a genetic or early event in
tumorigenesis. With tumor progression, the original requirement for
high level of CDK1 activation may not be necessary when more
favorable genetic and epigenetic changes occur. Under selective
pressure for survival, cancer cells with low CDK1 activation might
acquire advantages for expansion and metastasis (Figure 7B). This is
supported by recent observations, such as Cdk1 activity impaired by
the absence of Fez1/Lzts1 predisposes mice to cancer development
[38], inhibition of Cdk1 mediates protection from apoptosis in
C d c 2 0 - d e p l e t e dc e l l s[ 3 9 ] ,al o wr a t i oo fC D K 2t oC D K 1a c t i v i t yi s
associated with a favorable prognosis in breast cancer patients [40],
phosphorylation of p62by Cdk1is necessary torestraintumorigenesis
in vivo in response to Ras-induced transformation [41], and CDK1
inhibits cancer cell migration and invasion by phosphorylation of
EZH2 at Thr 487 [42].
Although CDK1 is perhaps the most interesting target identified
in our studies, other data also supports targeting TOP2A, PTTG1
and Survivin. For example, TOP2A gene expression is regulated
Figure 4. The associations of staining outcomes with tumor samples, clinical factors and patient survival. A. The hierarchial clustering
for both antibodies and tumors using Cluster 3.0 and Java TreeView. B. The positive rates of CDK1, PTTG1, Survivin and TOP2A in early stages (1–2)
and advanced stages (3–4). C. Kaplan-Meier survival analysis for cytoplasmic CDK1 staining pattern in NSCLC. The permutation test was used to
calculate the p value for all tumors and tumors by stage.
doi:10.1371/journal.pone.0023849.g004
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induced by mutant p53 might increase tumor aggressiveness [43].
Identification of TOP2A in our studies is consistent with the fact
that an inhibitor of topoisomerase II, etoposide, is approved for
treatment of advanced NSCLC. Although typically used in
combination with cisplatin, the response rate for single agent
etoposide in untreated NSCLC patients is 23% [44], which is
similar to the prevalence of TOP2A expression in NSCLC tumors
(Figure 3B). Because increased expression of TOP2A in immuno-
histochemistry can be associated with increased response to
etoposide in other tumor types, our studies suggest that expression
of TOP2A could be used to guide the application of etoposide
therapy [45].
PTTG1 is a homolog of yeast securin, which prevent separins
from promoting sister chromatid separation [16]. PTTG1 has
transforming activity in vitro and tumorigenic activity in vivo, and
the gene is highly expressed in various tumors [46]. Its oncogenic
effects may result from modulation of p53 function [47].
Overexpression of PTTG plays a role in the genesis and
progression of NSCLC [48].
Survivin is overexpressed in most human malignancies and
implicated in mitosis regulation and preservation of cell viability.
Mitochondrial Survivin inhibits apoptosis and promotes tumori-
genesis [49]. Its role during lung tumorigenesis is supported by
clinical data showing that Survivin transcripts are a defining
diagnostic marker for NSCLC [50], and that gene overexpression
is almost always present in early-stage NSCLC [51]. Our
observation that cytoplasmic Survivin is preferentially expressed
in stage 1 specimens is consistent with this. Although nuclear
Survivin is almost exclusively expressed in tumor tissues, no
clinical associations were observed. Conflicting observations have
been reported with survivin in that nuclear survivin can be
associated with better [52] or worse survival in NSCLC [53].
Taken together, our studies show that a comprehensive array
approach can be valuable to identify new targets in NSCLC. The
identification of cytoplasmic loss of CDK1 in lung cancer as an
independent poor prognostic factor in NSCLC patients is a
surprising finding with potential clinical significance in that CDK1
may play an important role in chemotherapeutic responsiveness
distinct from its role in cell cycle progression. Future studies will
assess the utility of stratifying patients and optimizing chemother-
apy in NSCLC protocols based on expression of TOP2A and
cytoplasmic CDK1.
Materials and Methods
Cell lines and drugs
NHBE, BEAS-2B [12], NNK-BEAS-2B [13] and H157 cells
were incubated at 37uCi n5 %C O 2. When cultures reached 90%
confluence, cells were harvested and frozen at 280uC prior to
RNA and protein isolation. NHBE cells were obtained from
Cambrex Bio Science Walkersville, Inc. (Walkersville, MD), and
Table 2. Associations of IHC staining, clinical factors and patient survival.
IHC CDK1-N CDK1-C PTTG1-N PTTG1-C Survivin-N Survivin-C TOP2A-N TOP2A-C
CDK1-N 6.89E-05 7.60E-10 5.10E-09 1.64E-05 4.33E-05 8.18E-12 7.81E-14
CDK1-C 0.00336 0.000187 – 9.62E-07 3.07E-05 0.000182
PTTG1-N 9.46E-09 2.70E-08 3.47E-05 6.75E-07 1.02E-06
PTTG1-C 3.11E-07 1.48E-22 6.75E-07 1.02E-06
Survivin-N 3.02E-07 0.000376 0.008537
Survivin-C 2.93E-05 2.84E-05
TOP2A-N 2.29E-24
TOP2A-C
Clinical
a g e – – –– ––––
gender – – – – – – – –
differentiation – – – – – – – –
size – – – – – – – 0.00745
a
stage – – – – – 0.0436
b ––
Survival
all histology – – – – – – – –
A D – – –– ––––
S C C – – –– ––––
,5 c m – – –– ––––
.= 5 c m – – –– ––––
stage 1–2 – – – – – – – –
stage 3–4 – 0.008
c –– ––––
overall – 0.04
d –– ––––
aCytoplasmic TOP2A staining was strongly associated with smaller tumors (,5c m ) .
bCytoplasmic Survivin staining was associated with stage I disease (stage 1.stage 2-3-4).
cLoss of cytoplasmic CDK1 staining at stage 3–4 was strongly associated with poor survival.
dLoss of cytoplasmic CDK1 staining was associated with poor survival.
doi:10.1371/journal.pone.0023849.t002
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(BEGM) containing 2 ml/ml bovine pituitary extract, 5 mg/ml
insulin, 0.5 mg/ml hydrocortisone, 0.5 ng/ml human epidermal
growth factor, 0.5 ml/ml epinephrine, 10 mg/ml transferrin,
0.1 ng/ml retinoic acid, 6.5 ng/ml triiodothyronine, 50 mg/ml
gentamycin and 50 ng/ml amphotericin-B. The BEAS-2B and
NNK-BEAS-2B were maintained with LHC-8 (Biofluids, MD)
with 100 units/ml penicillin and 100 mg/ml streptomycin
(GIBCO-BRL, Gaithersburg, MD). The H157 lung squamous
cell carcinoma cell line was provided by H. Oie and Dr. F. Kaye at
the National Cancer Institute/Naval Medical Oncology (Bethesda,
MD), were maintained in RPMI 1640 medium with 10% fetal
bovine serum with 100 units/ml penicillin and 100 mg/ml
streptomycin (GIBCO-BRL, Gaithersburg, MD). All the chemo-
therapy drugs were provided by NCI/Navy Medical Oncology.
RNA and protein isolation
RNA and protein were isolated from the same sample using
TRIzol reagent according to the manufacturer’s instructions
(Invitrogen, Carlsbad, CA). Briefly, 1 ml of TRIzol reagent was
Figure 5. Loss of CDK1 protein and activity and chemotherapeutic resistance. A. FT210 cells were serum-starvated in 0.1% FBS RPMI1640
medium overnight, then treated with 10 mM etoposide or cisplatin in 0.1% FBS containing medium for 4 days at 32uCo r3 9 uC. Apoptosis (sub-G1
DNA content) was determined by flow cytometry (C: Control; T: Treatment). B. FT210 cells were cultured in normal medium and treated with 1 mM
paclitaxel or docetaxel and 0.1 mM vinorelbine for 1–4 Days. The CDK1 protein was detected at Day 3 using CDK1 or p-Y15 CDK1 antibodies, and
apoptotic death was monitored by PARP cleavage. Apoptosis was determined at Day 4. C. FT210 and its parental cell line FM3A cells were cultured for
6 h then subjected to subcellular fractionation for immunoblotting analysis. aTubulin and p53 served as loading controls for cytoplasmic and nuclear
fractions, respectively. D. FM3A and FT210 cells were cultured at 39uC for 72 h and subjected to subcellular fractionation. Expression of CDK1, p-
Survivin (Thr34) and Survivin was assessed by immunoblotting. E. FM3A and FT210 cells were treated with 1 mM paclitaxel or docetaxel and 0.1 mM
vinorelbine. Apoptosis was determined at Day 4.
doi:10.1371/journal.pone.0023849.g005
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2 flask to lyse cells by rapid up and down pipetting
and subsequently incubated at room temperature for 5 min, then
mixed with 2/10 volume chloroform by vigorous shaking for
15 sec. Phase separation was achieved by placing the samples at
room temperature for 3 min, then centrifuging 3,500 rpm at 4uC
for 15 min. The RNA from the top aqueous layer was removed to
another 50 ml tube, slowly mixed with equal volume 70% ethanol,
and then transferred to RNeasy column (Qiagen, Inc., Valencia,
CA) for purification. The protein from the remainder layers was
precipitated, washed and dissolved according to the manufactur-
er’s instructions, and quantified by MicroBCA assay reagent kit
(Pierce, Rockford, IL). RNA was eluted from column with RNase-
free water, concentrated to .7 mg/ml by centrifugation on a
MicroCon YM-30 filter (Millipore, Billerica, MA), and quantified
using a UV/visible spectrophotometer Ultrospec3000 (Amersham
Biosciences, Piscataway, NJ). The integrity of total RNA was
verified by denaturing gel electrophoresis.
cDNA Microarray analysis
The cDNA microarrays contained over 28,798 cDNA clones
representing over 23,600 unique Unigene cluster and were
constructed as described [54]. Gene’s names are listed according
to Unigene build 141 (www.ncbi.nlm.nih.gov/unigene). Fluores-
cently labeled cDNA were synthesized from 100 mg RNA by
oligo(dT)-primed reverse transcription in the presence of Cy3- or
Cy5-dUTP (Amersham Bisciences, Piscataway, NJ), as described
[55], (http://www.nhgri.nih.gov/UACORE/index.html). Purified
Cy3/Cy5-labelled probes were combined and hybridized in the
presence of 26Denhart’s solution, 3.26saline sodium citrate
(SSC), and 0.5% sodium dodecyl sulfate (SDS) in a humidified
chamber at 65uC overnight. Prior to scanning (Agilent Technol-
ogies, Foster City, CA), slides were successively washed at 22uCi n
0.56SSC/0.1% SDS for 2 min, 0.56SSC/0.01% SDS for 2 min,
and 0.066SSC for 2 min. Image analyses were performed with
the IPLab software (Fairfax, VA). The reference cell (NHBE) was
Figure 6. Modulation of CDK1 protein level and activity and sensitivity of NSCLC cells to Paclitaxel treatment. A. CDK1 protein over or
under expressed in H157 cells. Cells were transfected with CDK1 plasmid or siRNA, 48 h or 72 h later, were treated with 1 mM paclitaxel for 2 days.
CDK1 protein level was monitored by CDK1 or p-Y15 CDK1 antibodies. Sub-G1 DNA content was determined by flow cytometry. B. Knockdown of
CDK1 in A549 cells. Cells were transfected with CDK1 siRNA, 72 h later, treated with 1 mM paclitaxel for 2 days. Apoptosis was determined by PARP
cleavage using immunoblotting or sub-G1 DNA content using flow cytometry. CDK1 protein level was monitored by CDK1 or p-Y15 CDK1 antibodies.
C. Overexpression of CDK1 or CDK1DN in A549 cells. Cells were transfected with CDK1 or CDK1DN plasmids, 48 h later, cell cycling stopped by
overnight pretreatment of low serum (0.1% FBS) medium with PI3K inhibitor LY294002 (10 mM), then cells were treated with 1 mM paclitaxel in low
serum medium containing LY294002 (10 mM, freshly added) for 2 days. Sub-G1 fraction and cell cycle profile were determined by flow cytometry.
Over expression of CDK1 and CDK1DN was detected by CDK1 antibody.
doi:10.1371/journal.pone.0023849.g006
Table 3. Correlation between CDK1 activating machinery components and chemotherapeutic agents in NCI60 cell line panel.
PCC (Ranked if PCC$0.200) CDC25A p-Y15 CDK1 p-T14 CDK1 CDK1 Cyclin B Cyclin A
MT1159 MT1161 MT1160 MT1158 MT1222 MT1167
Paclitaxel NSC125973 24.6 M 0.451 (1) 0.282 (3) 0.214 (6) 0.159 0.318 (2) 0.267 (4)
Docetaxel NSC628503 27.0 M 0.553 (1) 0.495 (2) 0.297 (5) 0.247 (6) 0.466 (3) 0.357 (4)
Etoposide NSC141540 23.0 M 0.394 (1) 0.259 (5) 0.036 0.148 0.136 0.202 (6)
Cisplatin NSC119875 24.3 M 0.134 0.167 20.060 20.096 20.105 0.285 (3)
A COMPARE analysis was performed by correlating protein levels of CDK1 activating machinery components with GI50 (concentration producing 50% growth inhibition)
values of chemotherapeutic agents in NCI60 human cancer cell lines. A positive Pearson Correlation Coefficient (PCC) indicates that the greater abundance of the target
may associate with sensitivity to the drug, whereas a negative correlation is indicative of more target conferring cellular resistance to the given drug.
doi:10.1371/journal.pone.0023849.t003
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normalization of each clone’s expression relative to the reference
for each cell line (BEAS-2B, NNK-BEAS-2B or H157). A self-to-
self hybridization with dye reversal was performed to exclude
preferential differences in probe labeling. Every sample was
labeled with Cy5 and Cy3 and hybridized twice. The two
fluorescent images (red and green channels) obtained from the
scanner constituted the intensity raw data from which differential
gene expression ratio and quality control values were calculated.
All data were entered into a relational database, using the
FileMaker Pro 5 software (Santa Clara, CA). Genes were identified
as differentially regulated only if corrected red/green hybridiza-
tion signals differed by at least twofold. The genes in each group
were alphabetically listed and the ratios of BEAS-2B/NHBE,
NNK-BEAS-2B/NHBE or H157/NHBE were graphically visu-
alized by Cluster and TreeView programs (http://rana.lbl.gov/
EisenSoftware.htm). These methods fulfilled the MIAME criteria
(http://www.mged.org/miame). The raw data were deposited in a
public functional genomics data repository Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/), and the GEO
accession number is GSE28282.
High-Throughput GoMiner analysis
To integrate information and illuminate patterns from multiple
microarrays in relationship to the Gene Ontology, High-
Throughput GoMiner (http://discover.nci.nih.gov/gominer/
htgm.jsp) analysis was performed following the instructions [56].
Immunoblotting
50 mg cellular proteins precipitated from NHBE, BEAS-2B,
NNK-BEAS-2B and H157 cells lysates were analyzed by
immunoblotting after SDS-PAGE electrophoresis. Individual
Figure 7. Dual role of CDK1 in tumorigenesis and chemotherapeutic sensitivity. A. A model of CDK1 activation. When inactive p-Y15/T14
CDK1 is dephosphorylated on Y15 and T14 by CDC25A, it associates with Cyclin A/B and becomes active within the cytoplasm, then quickly
translocates into the nucleus, where it promotes G1 to S and G2/M transitions. Active CDK1 is inactivated via sequential phosphorylation of Y15 and
T14 by Wee1 and Myt1, and sequestrated by 14-3-3s in the cytoplasm. This process repeats with cell cycling to drive cellular proliferation. B. A
diagram to illustrate the dual role of CDK1 as a tumorigenic driver in lung carcinogenesis and a sensitizer in chemotherapeutic responsiveness.
doi:10.1371/journal.pone.0023849.g007
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recognized CDK1, phospho-CDK1(Tyr15), FKHR, STMN1
(Cell signaling, MA), PLK1 (Upstate, Lake Placid, NY), Cyr61,
ETS1, p15, GKLF/KLF4, phospho-Thr34 Survivin (Santa Cruz
Biotechnology, Santa Cruz, CA), PERP, TRAIL (Poway, CA),
goat polyclonal antibodies that recognized PTTG1, PBK, hnRNP
A2/B1, galactin1, DNMT1, cyclin B2, HIP1, SPARC, S100A8,
or mouse monoclonal antibodies that recognized TOP2A (Roche,
IN), Survivin (Cell signaling, MA), maspin, TAO1 (BD Bioscience,
San Jose, CA), cyclin A, p63 (Santa Cruz Biotechnology, Santa
Cruz, CA) and KRT 14 (USBiological, Swampscott, MA). Rabbit
anti-human XAGE-1 polyclonal antibody was provided by Dr. Ira
Pastan (NCI). Immunocomplexes were visualized by SuperSignal
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL)
using goat anti-rabbit or mouse (Cell signaling, MA) or rabbit anti-
goat (Santa Cruz Biotechnology, Santa Cruz, CA) IgG coupled to
horseradish peroxidase as a secondary antibody.
Lung tissue microarray and immunohistochemical
staining
Three hundred lung cancer cases (150 pulmonary AD and 150
SCC cases) were selected from the Armed Forces Institute of
Pathology archive, and demographic and clinical data were
collected at the time of the paraffin block acquisition. A total of
246 patients had complete clinical information. Survival time and
outcome data were available for 211 patients. Approval for use of
the tissue in these research studies was obtained from both the
Institutional Review Boards of the Armed Forces Institute of
Pathology and the Office of Human Subjects Research of the
National Institutes of Health (Bethesda, MD). Approval for use of
the tissues in these studies was obtained from both the Institutional
Review Boards of the Armed Forces Institute of Pathology and the
Office of Human Subjects Research of the National Institutes of
Health (Bethesda, MD), who waived the need for consent since the
specimens were anonymized. The tumor were staged according to
the International Union against Cancer’s tumor-node-metastasis
(TNM) classification and histologically subtyped and graded
according to WHO guidelines. The most representative tumor
areas were carefully selected based on the matched H&E-stained
slides and marked directly on the donor block. One hundred
adjacent non-diseased lung tissues from AD and SCC cases, along
with 50 non-pulmonary normal tissues, were included in the same
array block. Immunochemical staining was carried out on this
tissue microarray using a standard avidin-biotin-perioxidase
complex technique (Vectastain Elite ABC kit; Vector Laboratory).
The optimized titer and specificity were determined using lung
sausage slides (FGMULTI-7; BioGenex) for each primary
antibody. The primary antibodies are mouse monoclonal (A17)
anti-p34 Cdc2 (CDK1) (ab18; abcam), mouse monoclonal (KiS1)
anti-topoisomerase II-alpha (TOP2A) (Roche), rabbit polyclonal
anti-human Pituitary Tumor-Transforming Gene (PTTG1)
(Zymed Laboratories Inc.) and mouse monoclonal (D-8) anti-
Survivin (sc-17779; Santa Cruz Biotech) antibodies, and at
dilutions of 1:125, 1:100, 1:50 and 1:10, respectively. The
optimized staining condition for lung tumor microarray was
determined based on the coexistence of both positive and negative
cells in the same tissue sample. The criteria for the staining were
scored as follows: distribution score was scored as 0 (0%), 1 (1–
50%; 1–10% for Survivin nuclear staining) and 2 (51–100%; 11–
100% for Survivin nuclear staining) to indicate the percentage of
positive cells in all tumor cells present in one tissue. The intensity
score was scored as 0 (no signal), 1 (weak), 2 (moderate) and 3
(marked). The total of distribution score and intensity score was
then summed into a total score (TS) of TS0 (sum=0), TS1
(sum=2), TS2 (sum=3), and TS3 (sum=4–5). TS0 or TS1 was
regarded as negative, and TS2 or TS3 was regarded as positive.
Degradation and inactivation of CDK1 from cytoplasm in
FT210 Cells
The murine carcinoma cell lines FM3A and FT210 [15] were
maintained in RPMI supplemented with fetal bovine serum (10%,
v/v) at 32uC. FT210 is a temperature-sensitive p34cdc2/Cdk1
mutant cell line derived from FM3A. For reducing the level and
activity of Cdk1, FT210 cells were cultured at the non-permissive
temperature of 39uC. FT210 cells were cultured at the permissive
temperature of 32uC as control. Its parent wild-type FM3A cells
were treated in the same way for comparison. For preparation of
cytoplasmic and nuclear extracts, 10610
6 cells were harvested,
washed and pelleted, then resuspended in 100 ml Lysis Buffer
(10 mM Tris?HCl, pH 8.0; 60 mM KCl; 1 mM EDTA; 0.5%
NP-40; 1 mM DTT, 0.2 mM PMSF and Protease Inhibitors
cocktail were freshly added). Incubated 5 min on ice, then
centrifuged 2300 rpm for 5 min at 4uC. Transferred and stored
the supernatant at 280uC. Added 40 ml of Nuclear Extract Buffer
(20 mM Tris?HCl, pH 8.0; 420 mM NaCl; 0.2 mM EDTA; 25%
glycerol; 1.5 mM MgCl2; 1 mM DTT, 0.2 mM PMSF and
Protease Inhibitors cocktail were freshly added) to the nuclear
pellet, and incubated on ice for 10 min. Centrifuge at 14,000 rpm
for 5 min at 4uC, transferred and stored nuclear extracts at
280uC. Then cytoplasmic and nuclear extracts were subjected to
immunoblotting analysis. CDK1 activity was monitored by
detecting the phosphorylation of Survivin on Thr34, a site for
CyclinB-CDK1 kinase, with p-Survivin (Thr34) antibody (Santa
Cruz Biotechnology, Inc.).
Pharmacologic treatments and apoptosis assay
To test chemotherapeutical response in Cdk1 degradation and
inactivation situations, FT210 or FM3A cells were cultured at
32uCo r3 9 uC for 1–4 days by adding etoposide (10 mM), cisplatin
(10 mM), paclitaxel (1 mM), docetaxel (1 mM) and vinorelbine
(0.1 mM). In etoposide and cisplatin treatments, the cells were
serum-starvated in 0.1% FBS medium overnight and treated in
0.1% FBS containing medium. Normal medium was used in all
microtubule-targeting reagents treatments. For CDK1 overex-
pression in H157 cells experiments, added the paclitaxel (1 mM) at
post-transfection 48 h and treated for another 48 h. In CDK1
knockdown in H157 and A549 cells experiments, added the same
concentration of paclitaxel at post-transfection 72 h and treated
for 48 h. The CDK1 overexpression or underexpression by
transfecting CDK1 plasmid or siRNA in H157 and A549 cells were
confirmed by immunoblotting, and related antibodies such as
p42MAPK, CDK1, Cleaved PARP and Wee1 were from Cell
Signaling Technology. For apoptosis analysis, floating cells and
adherent cells were harvested by trypsinization and then
centrifuged at 10006g for 5 min. Cells were fixed in ice-cold
70% methanol added dropwise and then incubated at 220uC for
30 min. Cells were centrifuged and incubated with propidium
iodide (25 mg/ml) supplemented with RNaseA (30 mg/ml) for
30 min at room temperature. Quantification of sub-G1 DNA
content was determined by flow cytometry analysis using a Becton
Dickinson FACSort and by manual gating using CellQuest
software. Apoptotosis experiments were performed in triplicate
and were independently repeated at least three times. The results
represent mean 6 SE from three independent experiments. The
difference of the comparison was tested using T-test with two
samples assuming equal variance, and p,0.001 was set as
significant.
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Plasmid DNA and siRNA duplex were delivered into the cells
by nucleofection technology (Lonza). Lung cancer cell lines H157
or A549 cells were maintained in RPMI1640+10% FBS and
harvested for nucleofection when reaching a 70,80 confluency.
The number of cells per nucleofection is 2610
6. The nucleofection
was performed using the nucleofector kit V with T-16 nucleofec-
tion program according to the manufacturer’s instructions. The
transfection efficiency was monitored by fluorescence using
pmaxGFP (about 98% for H157 and 80% for A549 positive rates
based on flow cytometry and microscopy analyses). 2 mg plasmid
constructs or siRNA double stranded RNA duplexes (16 ml1 0mM
siRNA) were used for each nucleofection. CDK1 wild type (pCMV-
cdc2WT) and dominant negative (pCMV-cdc2D146N) constructs
were provided by Drs. Sander van den Heuvel and Ed Harlow
(Massachusetts General Hospital). CDK1 and control siRNAs were
from Cell Signaling Technology.
NCI60 human cancer cell line COMPARE analysis
National Cancer Institute drug-screening panel of 60 human
cancer cells (NCI60) includes lung, colon, breast, ovarian,
leukemia, renal, melanoma, prostate and CNS cancer cells. To
ascertain the relevance of CDK1 to chemotherapeutic sensitivity
in a broad range, we performed COMPARE analysis. We used
paclitaxel (NSC125973) as a seed, 50% growth inhibition (GI50)
and 2-days as assay endpoint and time to search molecular targets
in NCI60 panel, and found CDK1 activator CDC25A, p-Y15/
T14 CDK1, CDK1, and CDK1 partners cyclin A/B were positive
associated paclitaxel drug sensitivity on the top of rank-order list.
We further used all the agents (vinorelbine/navelbine, NSC
608210, NCI60 set data is not available) we used in the
experiments and the above molecular targets to run MATRIX
COMPARE (http://itbwork.nci.nih.gov/PublicServer/jsp/Form_
Standard.jsp). Every compound has been done several times with
different cell line numbers (the highest log of GI50 concentration in
every assay is different), and every molecular target has primary and
log two forms, therefore there are a lot of combinations between
compounds and targets. Because the Pearson Correlation Coeffi-
cients (PCC) of the different combinations between individual
compound and target are similar, only one assay from each
compound and only log form (because the mean graph of drug
sensitivity is expressed as the logarithm of the concentration
resulting in 50% growth inhibition) of Western blot densitometry
from each targets were listed. The PCC was ranked on protein
targetlistwhenitwasnotlessthan0.200.Otherproteintargetswere
listed if their PCC have higher ranks than any ranked one of the
above targets.
Statistical analysis
Comparisons of clinical and pathological factors between
positive and negative groups were performed using the x
2 test.
The log-rank test was used for comparing survival distribution
between positive and negative groups of staining, and Kaplan-
Meier curves were plotted for the two groups. Association of
binary staining status between each pair of antibodies was
examined using the x
2 test, and the association was considered
significant if p#0.01. Association between antibody staining and
clinical factors was also analyzed using the x
2 test, where p#0.05
was considered significant.
Supporting Information
Figure S1 Gene expression changes in cell cycle and
checkpoint controls. DNA replication occurs in S phase and
chromosomes segregation into daughter progeny occurs in mitosis
(M phase). G1 and G2 are DNA synthesis and mitosis preparation
phases, respectively. In normal cells, cell cycle arrest occurs most
frequently at the G1/S and G2/M boundaries. Changes in gene
expression from groups A and J would be predicted to affect every
phase of the cell cycle. For example, increased expression of PCNA,
MCM7, Cyclin E2/A, CDK1, TPX2 and MAD2L1, and decreased
expression of 14-3-3s and CHK2 would be expected to promote G1
to S and G2 to M transitions, as well as escape from DNA damage-
induced arrest and cell cycle checkpoint control. Upregulation of
MCM3 and SMAD6 are associated with SV40-mediated immortal-
ization but are lost in fully transformed NNK-BEAS-2B cells.
Upregulation of ASK, CDC3A, Cyclin B2, PBK, 14-3-3e/g, BUB1 and
BUB1B, as well as downregulation of p21Cip1, is characteristic of
both types of transformed cells, indicating that the dysregulation of
cell cycle from S phase to mitosis might be more affected in the
process from immortalization to full transformation. NNK-specific
genes also encompassed the entire cell cycle because overexpression
of CDK4/2, CDC45/25B/20, CyclinG1/F, HDAC family members,
E2F family members, DP1, STK15, Survivin and PLK1,a n d
underexpression of GSK3b, FKHR, E2F6 and GADD45c were
observed. The cumulative effect of these changes in gene expression
would be predictedto increaseautonomous progression through the
cell cycle.
(TIF)
Figure S2 Gene expression changes in apoptosis path-
ways. Apoptosis can be initiated through either death receptors
on the cell surface (extrinsic) or mitochondria (intrinsic) pathways.
Induction of apoptosis leads to activation of the initiator caspase-8
and 10 (extrinsic) or 9 (intrinsic), which can activate executioner
caspases to cleave the death substrates and eventually results in
apoptosis. There are crosstalks between these two pathways.
Changes in gene expression during transformation also would be
predicted to alter the balance between apoptosis and cellular
survival. Apoptosis promoting factors such as TRAIL and PERP
were underexpressed in immortalized and transformed cells.
NNK-specific changes included increased expression of anti-
apoptotic factors DCR3, cIAP2, Survivin and BCL-X and decreased
expression of pro-apoptotic factors Granzyme B, TNFR1, TRAF1, C-
Jun, APAF-1 and Caspase-1. These NNK-induced alterations in
gene expression favored an anti-apoptotic trend that might
contribute to lung tumorigenesis.
(TIF)
Table S1 Classification of 1,688 regulated genes among
BEAS-2B(B), NNK-BEAS-2B(NB) and H157(H) compared
to NHBE(N).
(XLS)
Table S2 The genes involved in significantly changed
GeneOntology categories in BEAS-2B, NNK-BEAS-2B
and H157 compared to NHBE cells.
(XLS)
Table S3 The NNK-specific groups’ GeneOntology
categories and related genes.
(XLS)
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